Association of programmed death ligand 1 expression with prognosis among patients with ten uncommon advanced cancers

Torben Steiniche, Morten Ladekarl, Jeanette Baehr Georgsen, Simon Andreasen, Michael Busch-Sorensen, Wei Zhou, Matthew J Marton, Scott K Pruitt, Fan Jin, Kai-Li Liaw

Research output: Contribution to journalJournal articleResearchpeer-review

10 Citations (Scopus)
54 Downloads (Pure)

Abstract

Aim: PD-L1 expression and high levels of microsatellite instability (MSI-H) may predict response to checkpoint inhibitors, but their prevalence and prognostic value are unknown in many cancers. Methods: We retrospectively evaluated PD-L1 combined positive score (CPS) and MSI-H and their association with clinical outcomes among patients with ten advanced uncommon cancers. Results: 398 of 426 patients (93%) had a valid PD-L1 result; most (242; 61%) had CPS ≥1. Prevalence of MSI-H tumors was 8/360. Median overall survival was shorter among patients with PD-L1 CPS ≥1 tumors after first-line treatment (23.0 vs 39.7 months, p = 0.014). Conclusion: PD-L1 was commonly expressed in solid tumors, and CPS ≥1 was associated with shorter overall survival. Prevalence of MSI-H was low. Lay abstract Certain biologic characteristics of tumors (or biomarkers) may be used to assess the likely course of a patient's disease (i.e., their prognosis) and/or how they may respond to treatment. We evaluated whether the presence of the protein PD-L1 and high levels of microsatellite instability were associated with overall survival among patients with ten uncommon advanced cancers. PD-L1 was commonly expressed in solid tumors and its presence may be associated with shorter overall survival. Prevalence of high microsatellite instability was low.

Original languageEnglish
Article numberFSO616
JournalFuture Science OA
Volume6
Issue number8
Number of pages11
ISSN2056-5623
DOIs
Publication statusPublished - 19 Aug 2020

Bibliographical note

© 2020 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Keywords

  • anal carcinoma
  • biliary adenocarcinoma
  • cervical carcinoma
  • endometrial carcinoma
  • mesothelioma
  • neuroendocrine tumors
  • salivary gland carcinoma
  • small-cell lung carcinoma
  • thyroid carcinoma
  • vulvar carcinoma

Fingerprint

Dive into the research topics of 'Association of programmed death ligand 1 expression with prognosis among patients with ten uncommon advanced cancers'. Together they form a unique fingerprint.

Cite this